1. Radiotherapy (with temozolomide) is currently the standard of care for newly diagnosed glioblastoma. 2. Adjuvant PCV chemotherapy (methylbenzylhydrazine, lomustine, vincristine) is currently the standard of care for newly diagnosed mesenchymal oligodendroglioma containing 1p/19q co-deletions. 3. Chemotherapy is the standard of care for recurrent low-grade glioma and mesenchymal glioma. 4. For glioblastoma with MGMT promoter methylation, temozolomide chemotherapy is more effective than radiotherapy alone.5. Lomustine (CCNU) or rechemotherapy with temozolomide can be considered for recurrent glioblastoma.6. Bevacizumab combined with lomustine may play a role in the treatment of recurrent glioblastoma.7. To date, other targeted therapies for diffuse glioma Adjuvant PCV chemotherapy significantly improves survival in newly diagnosed high-risk low-grade gliomas.9 Temozolomide often replaces PCV regimens because it is well tolerated.10 Current cytotoxic agents are no longer likely to further improve the prognosis of gliomas, and new agents (including targeted) are urgently needed.